Drug
Retapamulin
Retapamulin is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
60%(3 trials)
Phase Distribution
Ph phase_3
1
17%
Ph phase_4
2
33%
Ph phase_2
1
17%
Phase Distribution
0
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
83.3%
5 of 6 finished
Non-Completion Rate
16.7%
1 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(5)
Terminated(1)
Detailed Status
Completed5
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (25.0%)
Phase 31 (25.0%)
Phase 42 (50.0%)
Trials by Status
completed583%
withdrawn117%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_3
Retapamulin as a Decolonizing Agent for MRSA
NCT03304873
withdrawnphase_4
Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization
NCT00856089
completedphase_4
Retapamulin for Reducing MRSA Nasal Carriage
NCT01461668
completedphase_2
Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus
NCT00539994
completed
United States Pharmacovigilence Retapamulin-Prescribing
NCT01153880
Clinical Trials (6)
Showing 6 of 6 trials
NCT03304873Phase 3
Retapamulin as a Decolonizing Agent for MRSA
NCT00856089Phase 4
Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization
NCT01461668Phase 4
Retapamulin for Reducing MRSA Nasal Carriage
NCT00539994Phase 2
Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus
NCT01153880
United States Pharmacovigilence Retapamulin-Prescribing
NCT01153828
EU PV for Retapamulin-Prescribing
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6